BioSpace News Archive

Cyclica announces a multi-year and multi-project collaboration with the Genome Institute of Singapore (GIS), a research institute under the Agency for Science, Technology and Research (A*STAR). Cyclica and GIS will carry out research efforts spanning from polypharmacology profiling to novel compound design for diverse drug discovery programs in oncology and related diseases. The collaboration will leverage GIS’

Lantheus Holdings, Inc. today announced that Lantheus has entered into a Support Agreement (the “Support Agreement”) with Velan Capital (“Velan”) in connection with the proposed merger of Lantheus and Progenics.

Five Prime Therapeutics, Inc. today announced the appointment of Thomas Civik as President and Chief Executive Officer and a member of the Board of Directors of the company. Mr. Civik joins Five Prime from

A new white paper, Undertaking Phase I Clinical Trials in Australia During a Time of Uncertainty, has been published by Nucleus Network (Nucleus), Australia’s largest Phase 1 clinical trials provider.

Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.